Vertex Reports Third-Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Vertex Pharma (VRTX) Tops Q3 EPS by 30c, Revenues Beat
October 29, 2020 4:02 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $2.64, $0.30 better than the analyst estimate of $2.34. Revenue for the quarter came in at $1.54 billion versus the consensus estimate of $1.48 billion.
"This has been another very strong quarter for Vertex with execution across our CF business and continued earnings and revenue growth," said Reshma... More
